Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLB002
MIFTS: 72

Glioblastoma

Categories: Rare diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Glioblastoma

About this section

MalaCards integrated aliases for Glioblastoma:

Name: Glioblastoma 53 59 29 55 6 73
Glioblastoma Multiforme 53 59 73
Gbm 59

Characteristics:

Orphanet epidemiological data:

59
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA360
MESH via Orphanet 45 D005909
UMLS via Orphanet 74 C0017636 C1621958
ICD10 via Orphanet 34 C71.9
UMLS 73 C1621958
Sources

Summaries for Glioblastoma

About this section
NIH Rare Diseases : 53 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome. There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy.

MalaCards based summary : Glioblastoma, also known as glioblastoma multiforme, is related to glioblastoma multiforme and giant cell glioblastoma, and has symptoms including headache and seizures. An important gene associated with Glioblastoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Cytokine Signaling in Immune system. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are abnormal cell morphology and visual loss

Wikipedia : 76 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Sources

Related Diseases for Glioblastoma

About this section

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 glioblastoma multiforme 36.3 EGFR MIR137 MIR21 MIR221 MTOR PIK3CA
2 giant cell glioblastoma 36.1 BRAF EGFR PTEN TP53
3 gliosarcoma 34.8 EGFR PTEN TP53
4 gliomatosis cerebri 34.4 EGFR PTEN TP53
5 glioma 33.0 BRAF EGFR MIR21 MIR221 MIR222 MIR296
6 grade iii astrocytoma 32.8 EGFR PTEN TP53
7 pilocytic astrocytoma 32.7 BRAF HRAS PIK3CA PTEN TP53
8 brain cancer 32.6 BRAF EGFR HRAS NRAS PIK3CA PTEN
9 medulloblastoma 32.5 EGFR MIR326 MIR34A NRAS PIK3CA PTEN
10 adenocarcinoma 32.3 BRAF EGFR HRAS PIK3CA PTEN TP53
11 melanoma 32.2 BRAF MIR137 MIR182 MIR221 MIR222 MIR34A
12 oligodendroglioma 32.1 EGFR PTEN TP53
13 sarcoma 32.1 BRAF HRAS PIK3CA TP53
14 lung cancer 32.0 BRAF EGFR HRAS MIR137 MIR182 MIR21
15 prostate cancer 32.0 EGFR HRAS MIR182 MIR21 MIR221 MIR222
16 neuroblastoma 32.0 MIR221 MIR34A NRAS PIK3CA TP53
17 breast cancer 31.9 BRAF EGFR HRAS MIR182 MIR21 MIR221
18 pancreatic cancer 31.9 EGFR HRAS MIR21 MIR221 MIR222 MIR34A
19 ovarian cancer 31.9 BRAF EGFR MIR21 MIR221 MIR222 MIR296
20 hepatocellular carcinoma 31.8 EGFR HRAS MIR137 MIR182 MIR21 MIR221
21 lung cancer susceptibility 3 31.8 BRAF EGFR HRAS NRAS PIK3CA TP53
22 thyroid cancer 31.8 BRAF HRAS NRAS PIK3CA PTEN TP53
23 cholangiocarcinoma 31.7 EGFR HRAS MIR21 PIK3CA PTEN TP53
24 small cell carcinoma 31.7 EGFR PTEN TP53
25 small cell cancer of the lung 31.7 EGFR MIR21 PIK3CA PTEN TP53
26 colorectal cancer 31.7 BRAF EGFR HRAS MIR137 MIR182 MIR21
27 leukemia, chronic lymphocytic 31.6 BRAF HRAS MIR21 MIR221 MIR34A NRAS
28 li-fraumeni syndrome 31.5 EGFR PTEN TP53
29 bladder cancer 31.5 EGFR HRAS MIR21 MIR221 MIR222 TP53
30 lymphoma, non-hodgkin, familial 31.4 BRAF NRAS PIK3CA TP53
31 testicular germ cell tumor 31.4 BRAF PTEN TP53
32 thyroid cancer, nonmedullary, 1 31.4 BRAF MIR21 MIR221 MIR222 MIR34A
33 leukemia, acute lymphoblastic 31.3 MIR21 MIR221 MIR222 MIR451A
34 pancreatic neuroendocrine tumor 31.2 MTOR PIK3CA
35 brain glioblastoma multiforme 12.1
36 glioblastoma proneural subtype 12.1
37 glioblastoma classical subtype 12.1
38 glioblastoma mesenchymal subtype 12.1
39 glioblastoma neural subtype 12.1
40 glioma susceptibility 1 12.0
41 adult spinal cord glioblastoma multiforme 11.9
42 goodpasture syndrome 11.9
43 renal cell carcinoma, papillary, 1 11.8 BRAF HRAS MTOR NRAS PIK3CA PTEN
44 gastric adenocarcinoma 11.8 BRAF EGFR HRAS NRAS PIK3CA PTEN
45 endometrial cancer 11.8 BRAF EGFR HRAS MTOR PIK3CA PTEN
46 lung squamous cell carcinoma 11.8 BRAF EGFR HRAS PIK3CA PTEN TP53
47 skin melanoma 11.8 BRAF HRAS NRAS PIK3CA PTEN TP53
48 female reproductive organ cancer 11.8 EGFR HRAS PIK3CA PTEN TP53
49 respiratory system cancer 11.7 EGFR HRAS PIK3CA PTEN TP53
50 uterine carcinosarcoma 11.7 EGFR HRAS PIK3CA PTEN TP53

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma
Sources

Symptoms & Phenotypes for Glioblastoma

About this section

Human phenotypes related to Glioblastoma:

59 32 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal cell morphology 59 32 hallmark (90%) Very frequent (99-80%) HP:0025461
2 visual loss 59 32 frequent (33%) Frequent (79-30%) HP:0000572
3 abnormality of the corpus callosum 59 32 frequent (33%) Frequent (79-30%) HP:0001273
4 muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0001324
5 mood changes 59 32 frequent (33%) Frequent (79-30%) HP:0001575
6 cerebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0002181
7 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
8 language impairment 59 32 frequent (33%) Frequent (79-30%) HP:0002463
9 paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0003470
10 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
11 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
12 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
13 glioblastoma 59 Obligate (100%)
14 abnormality of the cerebral white matter 59 Frequent (79-30%)
15 abnormality of nervous system physiology 59 Frequent (79-30%)
16 glioblastoma multiforme 32 obligate (100%) HP:0012174

UMLS symptoms related to Glioblastoma:


headache, seizures

GenomeRNAi Phenotypes related to Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.54 PIK3CA HRAS BRAF MTOR EGFR
2 Decreased viability GR00221-A-1 10.54 PIK3CA MTOR HRAS NRAS EGFR
3 Decreased viability GR00221-A-2 10.54 PIK3CA HRAS
4 Decreased viability GR00221-A-3 10.54 HRAS NRAS
5 Decreased viability GR00221-A-4 10.54 PIK3CA MTOR BRAF EGFR
6 Decreased viability GR00301-A 10.54 BRAF
7 Decreased viability GR00342-S-1 10.54 MTOR
8 Decreased viability GR00342-S-2 10.54 MTOR
9 Decreased viability GR00381-A-1 10.54 BRAF
10 Decreased viability GR00402-S-2 10.54 PIK3CA HRAS NRAS BRAF MTOR EGFR
11 Decreased cell migration GR00055-A-1 9.72 PIK3CA HRAS BRAF EGFR MTOR
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 PTEN EGFR MTOR NRAS HRAS
13 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
14 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.35 MTOR EGFR
16 Increased cell migration GR00055-A-3 9.02 PIK3CA HRAS BRAF MTOR EGFR

MGI Mouse Phenotypes related to Glioblastoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.13 TP53 PIK3CA HRAS PTEN MTOR BCOR
2 endocrine/exocrine gland MP:0005379 10.02 PTEN TP53 PIK3CA HRAS MTOR BRAF
3 embryo MP:0005380 10.01 PTEN TP53 PIK3CA BCOR MTOR BRAF
4 adipose tissue MP:0005375 10 TP53 PTEN MTOR BRAF NOS2 EGFR
5 integument MP:0010771 9.92 PTEN TP53 EGFR PIK3CA HRAS NOS2
6 neoplasm MP:0002006 9.86 TP53 HRAS PTEN BRAF NOS2 NRAS
7 pigmentation MP:0001186 9.55 PTEN TP53 BRAF NRAS EGFR
8 renal/urinary system MP:0005367 9.5 PTEN TP53 HRAS MTOR BRAF NOS2
9 skeleton MP:0005390 9.28 PTEN TP53 PIK3CA HRAS MTOR BRAF
Sources

Drugs & Therapeutics for Glioblastoma

About this section

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 591)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
8
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
9
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
10
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
11
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
12
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
13
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
14
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
15
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
16
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
17
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
18
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
19
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
20
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
21
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
22
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
23
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
24
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
25
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
26
Copper Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
27
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
30
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
31
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
32
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
33
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
34
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
35
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
36
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
39
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
40
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
41
Dopamine Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
42
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
43
Povidone-iodine Approved Phase 3 25655-41-8
44
Povidone Approved Phase 3 9003-39-8
45
Losartan Approved Phase 3 114798-26-4 3961
46
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
47
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
48
Ephedrine Approved Phase 3 299-42-3 9294
49
Pseudoephedrine Approved Phase 3 90-82-4 7028
50
Norepinephrine Approved Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 1337)
# Name Status NCT ID Phase Drugs
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
4 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
6 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
7 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
8 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
9 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
10 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
11 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
12 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
13 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
14 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
15 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
16 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
17 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
18 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
19 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
20 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
21 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
22 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
23 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
24 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
25 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
26 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
27 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
28 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
29 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
30 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
31 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
32 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
33 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3 TransMID
34 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
35 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
36 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
37 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
38 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
39 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
40 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
41 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
42 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
43 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3 Temozolomide
44 Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy Recruiting NCT03548571 Phase 2, Phase 3 Adjuvant temozolomide
45 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Recruiting NCT03393000 Phase 3 Trans Sodium Crocetinate plus SOC
46 Disulfiram in Recurrent Glioblastoma Recruiting NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
47 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Recruiting NCT02761070 Phase 3 Temozolomide;Bevacizumab
48 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification ( Intellance1 ) Recruiting NCT02573324 Phase 3 Temozolomide;ABT-414;Placebo for ABT-414
49 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) Recruiting NCT03291977 Phase 3 Fluorescéine Sodique Faure
50 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Recruiting NCT02667587 Phase 3 Nivolumab;Temozolomide

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Glioblastoma

About this section

Genetic tests related to Glioblastoma:

# Genetic test Affiliating Genes
1 Glioblastoma 29
Sources

Anatomical Context for Glioblastoma

About this section

MalaCards organs/tissues related to Glioblastoma:

41
Brain, T Cells, Endothelial, Testes, Bone, Spinal Cord, Prostate
Sources

Publications for Glioblastoma

About this section

Articles related to Glioblastoma:

(show top 50) (show all 4402)
# Title Authors Year
1
Glioblastoma multiforme subterfuge as acute cerebral hemorrhage: A case report and literature review. ( 29844891 )
2018
2
Evaluation of the relationship of erythrocyte membrane Na+/K+-ATPase enzyme activity and tumor response to chemoradiotherapy in patients diagnosed with locally advanced nonsmall cell lung cancer and glioblastoma multiforme. ( 29970705 )
2018
3
3-O-acetyl-11-keto-I^-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. ( 29970196 )
2018
4
Sodium butyrate induces senescence and inhibits the invasiveness of glioblastoma cells. ( 29434841 )
2018
5
BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. ( 29977042 )
2018
6
Benzyl isothiocyanate inhibits human brain glioblastoma multiforme GBM 8401 cell xenograft tumor in nude mice in vivo. ( 29972272 )
2018
7
Highlighting the need for reliable clinical trials in glioblastoma. ( 29973092 )
2018
8
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. ( 29979390 )
2018
9
Venous thromboembolic complications with and without intermittent intraoperative and postoperative pneumatic compression in patients with glioblastoma multiforme using intraoperative magnetic resonance imaging. A retrospective study. ( 29859696 )
2018
10
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
11
Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival. ( 29434344 )
2018
12
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. ( 29963263 )
2018
13
Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. ( 29444555 )
2018
14
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( 29502931 )
2018
15
microRNAa89574 inhibits cell proliferation and invasion in glioblastoma multiforme by directly targeting zinc finger Ea89boxa89binding homeobox 1. ( 29901177 )
2018
16
Specifically Targeted Electromagnetic Fields Arrest Proliferation of Glioblastoma Multiforme U-87 Cells in Culture. ( 29848672 )
2018
17
Enhanced and preferential internalization of lipid nanocapsules into human glioblastoma cells: effect of a surface-functionalizing NFL peptide. ( 29972178 )
2018
18
Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. ( 28926136 )
2018
19
A case of subgaleal metastasis from glioblastoma multiforme. ( 29898273 )
2018
20
MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating I^-catenin and causing activation of FOXO3a. ( 29399110 )
2018
21
Does radiation therapy increase gadolinium accumulation in the brain?: Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. ( 29444157 )
2018
22
Evaluation of Targeted Curcumin (CUR) loaded PLGA Nanoparticles for in vitro Photodynamic Therapy on Human Glioblastoma Cell Line. ( 29969678 )
2018
23
Combining Perfusion and High B-value Diffusion MRI to Inform Prognosis and Predict Failure Patterns in Glioblastoma. ( 29980414 )
2018
24
Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. ( 29953855 )
2018
25
Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. ( 29899827 )
2018
26
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. ( 28266716 )
2018
27
Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells. ( 29434995 )
2018
28
Long noncoding RNA SNHG7 promotes the progression and growth of glioblastoma via inhibition of miR-5095. ( 29360452 )
2018
29
Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. ( 29416731 )
2018
30
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. ( 29366782 )
2018
31
Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3-kinase/protein kinase B signaling. ( 29977365 )
2018
32
Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. ( 29444930 )
2018
33
Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma. ( 29769456 )
2018
34
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C<sub>12</sub>and HNK for Glioblastoma Multiforme Chemotherapy. ( 29397747 )
2018
35
Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. ( 29330078 )
2018
36
Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI. ( 29372508 )
2018
37
Transmission of a <i>TP53</i> germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner. ( 29581140 )
2018
38
Enhanced radiosensitization of human glioblastoma multiforme cells with phosphorylated peptides derived from Gli2. ( 29880393 )
2018
39
Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Glioblastoma of the Corpus Callosum. ( 29438526 )
2018
40
A case of epidural glioblastoma metastasis presenting with a cervical myelopathy, torticollis, and L'hermitte's phenomenon. ( 29744614 )
2018
41
Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma. ( 29532523 )
2018
42
Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. ( 29442128 )
2018
43
Closed Stereotactic Needle Biopsy of Brainstem Small Cell Glioblastoma: A Case Report and Literature Review. ( 29974014 )
2018
44
Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. ( 29387965 )
2018
45
Impact of PKCI/ downregulation on autophagy in glioblastoma cells. ( 29439667 )
2018
46
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. ( 29971562 )
2018
47
An Extracranial Metastasis of Glioblastoma Mimicking Mucoepidermoid Carcinoma. ( 29852299 )
2018
48
Perphenazine and prochlorperazine induce concentration-dependent loss in human glioblastoma cells viability. ( 29441946 )
2018
49
Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. ( 29162448 )
2018
50
A Rare Case of Concurrent Herpes Simplex Encephalitis and Glioblastoma Multiforme. ( 29492128 )
2018
Sources

Variations for Glioblastoma

About this section

ClinVar genetic disease variations for Glioblastoma:

6
(show top 50) (show all 447)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh37 Chromosome 10, 89717672: 89717672
2 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh38 Chromosome 10, 87957915: 87957915
3 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
4 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
9 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
10 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
11 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
12 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
13 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
14 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
15 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
16 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
17 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
18 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
19 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
20 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
21 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
22 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
23 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
24 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
25 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
28 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
29 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
31 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
32 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
33 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
34 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
35 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
36 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
37 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
38 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
39 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
40 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
42 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
43 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
44 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
45 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
46 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
47 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
48 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
49 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
50 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605

Copy number variations for Glioblastoma from CNVD:

7 (show all 37)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13758 1 1 28000000 Copy number Glioblastoma
2 30312 1 241718157 242073207 Amplification AKT3 Glioblastoma
3 33636 1 46800000 50700000 Copy number Glioblastoma
4 40021 10 123227833 123347962 Amplification FGFR2 Glioblastoma
5 42796 10 40200000 135534747 Loss Glioblastoma
6 51519 11 127400000 130300000 Loss Glioblastoma
7 70074 12 58100000 63100000 Copy number CDK4 Glioblastoma
8 71138 12 67700000 71500000 Copy number MDM2 Glioblastoma
9 74585 13 109204184 109236915 Amplification IRS2 Glioblastoma
10 87860 14 78400000 100400000 Loss Glioblastoma
11 106844 17 1 3600000 Loss Glioblastoma
12 109487 17 26446120 26728821 Deletion NF1 Glioblastoma
13 122049 18 52000000 76117153 Loss Glioblastoma
14 132099 19 57600000 63811651 Gain Glioblastoma
15 133731 19 6900000 13900000 Copy number CDKN2D Glioblastoma
16 137039 2 136600000 209100000 Gain Glioblastoma
17 187590 4 52700000 59500000 Amplification CHIC2 Glioblastoma
18 187591 4 52700000 59500000 Amplification IGFBP7 Glioblastoma
19 187592 4 52700000 59500000 Amplification KDR Glioblastoma
20 187593 4 52700000 59500000 Amplification KIT Glioblastoma
21 187594 4 52700000 59500000 Amplification KIT Glioblastoma
22 187596 4 52700000 59500000 Amplification LNX1 Glioblastoma
23 187597 4 52700000 59500000 Amplification PDGFRA Glioblastoma
24 187598 4 52700000 59500000 Amplification PDGFRA Glioblastoma
25 187599 4 52700000 59500000 Amplification RASL11B Glioblastoma
26 187600 4 52700000 59500000 Amplification REST Glioblastoma
27 187601 4 52700000 59500000 Amplification SEC3L1 Glioblastoma
28 187602 4 52700000 59500000 Amplification USP46 Glioblastoma
29 187603 4 52700000 59500000 Amplification VEGFR2 Glioblastoma
30 187604 4 52700000 59500000 Copy number Glioblastoma
31 207847 6 161688579 163068824 Deletion PARK2 Glioblastoma
32 226025 7 54000000 58000000 Copy number EGFR Glioblastoma
33 226576 7 59600001 66100000 Gain Glioblastoma
34 250055 9 19900000 33200000 Copy number CDKN2A Glioblastoma
35 253823 9 4600000 14200000 Deletion PTPRD Glioblastoma
36 253952 9 49000000 141213431 Loss Glioblastoma
37 255680 9